Hims & Hers Abandons Cheaper Wegovy Knockoff After FDA Warning

Telehealth company drops plan to offer compounded version of weight-loss drug following regulatory threats.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Telehealth company Hims & Hers has abandoned its plan to offer a compounded version of the weight-loss drug Wegovy, just two days after announcing the new product. The decision came after the FDA threatened to restrict access to the active ingredients needed to copy popular GLP-1 medications like Wegovy.

Why it matters

The Wegovy weight-loss medication has seen surging demand, prompting companies like Hims & Hers to try offering cheaper, compounded versions. However, the FDA has now signaled it will take steps to limit access to the active ingredients, potentially curbing the ability of telehealth firms to undercut the original drug's price.

The details

Hims & Hers had planned to sell a compounded version of Wegovy for $49 per month, significantly undercutting Novo Nordisk's $149 per month price for the FDA-approved drug. However, the FDA warned it would restrict access to the active ingredient semaglutide, prompting Hims to abandon the plan just a day later. The telehealth company had touted the new offering on its website before abruptly reversing course.

  • On March 7, 2026, Hims & Hers announced plans to offer a compounded version of Wegovy.
  • On March 8, 2026, the FDA threatened to limit access to the active ingredients needed to copy GLP-1 weight-loss drugs like Wegovy.
  • On March 9, 2026, Hims & Hers announced it would no longer sell the compounded Wegovy product.

The players

Hims & Hers

A telehealth company that had planned to offer a compounded version of the weight-loss drug Wegovy at a lower price than the original.

Novo Nordisk

The pharmaceutical company that manufactures the FDA-approved Wegovy weight-loss medication, which it sells for $149 per month.

Food and Drug Administration (FDA)

The U.S. regulatory agency that threatened to restrict access to the active ingredients needed to produce compounded versions of popular GLP-1 weight-loss drugs like Wegovy.

Got photos? Submit your photos here. ›

What they’re saying

“Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment.”

— Hims & Hers (X)

What’s next

The FDA is expected to take decisive steps to limit access to the active ingredients needed to produce compounded versions of GLP-1 weight-loss drugs like Wegovy, potentially curbing the ability of telehealth firms to undercut the original drug's price.

The takeaway

This case highlights the tension between affordable access to medications and the regulatory oversight needed to ensure drug safety and efficacy. The booming demand for weight-loss drugs has prompted some companies to seek shortcuts, but the FDA is now moving to reassert its authority and protect the integrity of the pharmaceutical market.